Growth Hormone Biotech Seeks $86M IPO Amid Strong Market
Venture capital-backed drug company Ascendis Pharma, a Danish developer of treatments for human growth hormone deficiency, filed Thursday for an $86.25 million initial public offering in the U.S., marking the latest...To view the full article, register now.
Already a subscriber? Click here to view full article